银屑病关节炎一线肿瘤坏死因子抑制剂疗效的性别差异:欧洲脊柱关节炎研究协作网络结果
该研究汇总欧洲13个脊柱关节炎研究协作网络注册库中起始首种肿瘤坏死因子抑制剂(TNFi)的银屑病关节炎(PsA)患者数据,分析性别与治疗反应及药物留存率的关联。6个月时女性低疾病活动度(LDA)比例为64%,男性为78%(相对风险RR 0.82,95%CI 0.80-0.84),校正后RR 0.83(95%CI 0.81-0.85);女性TNFi留存率在所有时间点均显著低于男性。
要点
- 6个月时女性LDA比例64%,男性78%,RR 0.82(95%CI 0.80-0.84),校正后RR 0.83(95%CI 0.81-0.85)。
- 女性TNFi留存率在6、12、24个月分别为79%、64%、50%,均低于男性(88%、77%、64%)。
- 基线特征相似,但女性患者报告结局指标更差。
核心结论
- 尽管基线疾病特征相当,女性PsA患者对首种TNFi的治疗反应和留存率均低于男性,提示在PsA研究和管理中需考虑性别差异。
研究设计与样本
- 汇总欧洲13个脊柱关节炎研究协作网络注册库中起始首种TNFi的PsA患者数据,采用逻辑回归分析性别与治疗反应的关联,以6个月时基于DAS28-CRP的低疾病活动度(LDA,<3.2)为主要结局,校正年龄、国家、传统合成改善病情抗风湿药治疗和TNFi起始年份;采用Kaplan-Meier法评估留存率。
主要发现
- 分析7,679例有6个月LDA数据的PsA患者(女性占50%);基线平均DAS28-CRP女性为4.4(SD 1.2),男性为4.2(SD 1.2),女性患者报告结局指标更差。
- 6个月时女性LDA比例为64%,男性为78%(RR 0.82,95%CI 0.80-0.84);校正后差异相似(RR 0.83,95%CI 0.81-0.85)。
- 在17,842例PsA患者中评估TNFi留存率,女性在6、12、24个月均显著低于男性(女性79%、64%、50% vs 男性88%、77%、64%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Women with psoriatic arthritis (PsA) may have reduced tumor necrosis factor inhibitor (TNFi) effectiveness compared to men. We examined sex differences in treatment response and retention rates during 24 months of follow-up among patients with PsA initiating their first TNFi. METHODS: Data from patients with PsA across 13 European Spondyloarthritis Research Collaboration Network registries starting their first TNFi were pooled. Logistic regression was used to analyze the association between sex and treatment response using low disease activity (LDA) according to the Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP) (<3.2) at six months as the primary outcome. Analyses were adjusted for age, country, conventional synthetic disease-modifying antirheumatic drug treatment, and TNFi start year. Retention rates were explored using the Kaplan-Meier estimator. RESULTS: We analyzed the treatment response of 7,679 patients with PsA (50% women) with available data on LDA at six months. At baseline, women and men had similar characteristics, including mean DAS28-CRP (women vs men, 4.4 [SD 1.2] vs 4.2 [SD 1.2]), though patient-reported outcome measures were worse in women. At six months, 64% of women and 78% of men had LDA (relative risk [RR] 0.82; 95% confidence interval [CI] 0.80-0.84). This difference was similar after adjustment (RR 0.83; 95% CI 0.81-0.85). TNFi retention rates were evaluated in 17,842 patients with PsA. Women had significantly lower retention rates than men at all time points (women 79%, 64%, and 50% vs men 88%, 77%, and 64% at 6, 12, and 24 months, respectively). CONCLUSION: Despite comparable disease characteristics at baseline, women with PsA have reduced treatment response and retention rates to their first TNFi, highlighting the need to consider sex differences in PsA research and management.
引用
- Hellamand P, van de Sande MGH, Ørnbjerg LM, et al. Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network. Arthritis Rheumatol. 2024. PMID: 37975166. doi:10.1002/art.42758
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。